|国家预印本平台
首页|自体免疫细胞治疗临床研究进展

自体免疫细胞治疗临床研究进展

Progress in clinical research of autologous immune cell therapy

中文摘要英文摘要

在过去几年中,免疫治疗在多种类型的癌症治疗中起到了关键性的作用。过继性免疫细胞治疗是免疫治疗的一种,包括细胞因子诱导的杀伤细胞(CIK)治疗、自体活化的淋巴细胞(AAL)治疗、细胞毒性T淋巴细胞(CTL)治疗、树突状细胞(DC)治疗和嵌合抗原受体(CAR-T)治疗。通过体外培养或基因修饰患者自体免疫细胞,大量扩增后,具有活性的自体免疫细胞回输到患者体内杀伤肿瘤。大量的临床数据表明这种方法对癌症病人非常行之有效。本文我们将简要综述不同过继性免疫细胞的制备方法和对癌细胞的杀伤机制。为进一步系统地开展过继性细胞免疫治疗的临床应用,特别是过继性免疫细胞疗法联合常规的放疗及化疗提供重要参考。因此,具有重要的科学和临床实用价值。

In passed few years immunotherapy has played a critical role in treating most types of cancer. Adoptive immnue cell therapy is one of the hotest cancer immunotherapy, including therapies of Cytokine-induced Killer Cells (CIKs), Autologous activated lymphocyte(AAL), Cytotoxic T Lympercytes (CTLs), Dentritic Cells(DCs) and Chimeric Antigen Receptor T-cell (CAR-T). Through transfused cytokines stimulation or gene modification of in-vitro cultured autologous immune cells,the activated immnue cells kill tumour cell to eradicate tumor in patients. A large number of clinical data already proved the potent efficiency of this kind of treatment in various cancer patients. In this review, we focus on the adoptive immune cell preparation and the main cancer cell killing mechanism. Here we refer an important referential value for futher studying on adoptive immunotherapy in clinic, especially cooperating with radiotherapy and chemotherapy. Thus, it has important values on science and clinical application.

吴金芸、蔡茂怀、周立莉

肿瘤学临床医学细胞生物学

免疫细胞治疗肿瘤-CIKR-T联合治疗

immunotherapytumorDC-CIKCAR-Tcombined therapy

吴金芸,蔡茂怀,周立莉.自体免疫细胞治疗临床研究进展[EB/OL].(2016-10-25)[2025-08-02].http://www.paper.edu.cn/releasepaper/content/201610-173.点此复制

评论